Cargando…
A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation
Objective: To assess the feasibility of a combination of biochemical and imaging parameters for estimation of risk and severity of coronary atherosclerosis (CA), and to verify the created integrated biomarker (i-BIO) on independent cohort. Methods: Two cohorts of patients admitted to the hospital fo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877383/ https://www.ncbi.nlm.nih.gov/pubmed/35207694 http://dx.doi.org/10.3390/jpm12020206 |
_version_ | 1784658407841595392 |
---|---|
author | Metelskaya, Victoria A. Gavrilova, Natalia E. Zhatkina, Maria V. Yarovaya, Elena B. Drapkina, Oxana M. |
author_facet | Metelskaya, Victoria A. Gavrilova, Natalia E. Zhatkina, Maria V. Yarovaya, Elena B. Drapkina, Oxana M. |
author_sort | Metelskaya, Victoria A. |
collection | PubMed |
description | Objective: To assess the feasibility of a combination of biochemical and imaging parameters for estimation of risk and severity of coronary atherosclerosis (CA), and to verify the created integrated biomarker (i-BIO) on independent cohort. Methods: Two cohorts of patients admitted to the hospital for coronary angiography and ultrasound carotid dopplerography were enrolled into the study (n = 205 and n = 216, respectively). The extent of CA was assessed by Gensini Score (GS). Results: According to GS, participants were distributed as follows: atherosclerosis-free (GS = 0), CA of any stage (GS > 0), subclinical CA (GS < 35), severe CA (GS ≥ 35). Based on the analysis of mathematical models, including biochemical and imaging parameters, we selected and combined the most significant variables as i-BIO. The ability of i-BIO to detect the presence and severity of CA was estimated using ROC-analysis with cut-off points determination. Risk of any CA (GS > 0) at i-BIO > 4 was 7.3 times higher than in those with i-BIO ≤ 4; risk of severe CA (GS ≥ 35) at i-BIO ≥ 9 was 3.1 times higher than at i-BIO < 9. Results on the tested cohort confirmed these findings. Conclusions: The i-BIO > 4 detected CA (GS > 0) with sensitivity of 87.9%, i-BIO ≥ 9 excluded patients without severe CA (GS < 35), specificity 79.8%. Validation of i-BIO confirmed the feasibility of i-BIO > 4 to separate patients with any CA with sensitivity 76.2%, and of i-BIO ≥ 9 to exclude atherosclerosis-free subjects with specificity of 84.0%. |
format | Online Article Text |
id | pubmed-8877383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88773832022-02-26 A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation Metelskaya, Victoria A. Gavrilova, Natalia E. Zhatkina, Maria V. Yarovaya, Elena B. Drapkina, Oxana M. J Pers Med Article Objective: To assess the feasibility of a combination of biochemical and imaging parameters for estimation of risk and severity of coronary atherosclerosis (CA), and to verify the created integrated biomarker (i-BIO) on independent cohort. Methods: Two cohorts of patients admitted to the hospital for coronary angiography and ultrasound carotid dopplerography were enrolled into the study (n = 205 and n = 216, respectively). The extent of CA was assessed by Gensini Score (GS). Results: According to GS, participants were distributed as follows: atherosclerosis-free (GS = 0), CA of any stage (GS > 0), subclinical CA (GS < 35), severe CA (GS ≥ 35). Based on the analysis of mathematical models, including biochemical and imaging parameters, we selected and combined the most significant variables as i-BIO. The ability of i-BIO to detect the presence and severity of CA was estimated using ROC-analysis with cut-off points determination. Risk of any CA (GS > 0) at i-BIO > 4 was 7.3 times higher than in those with i-BIO ≤ 4; risk of severe CA (GS ≥ 35) at i-BIO ≥ 9 was 3.1 times higher than at i-BIO < 9. Results on the tested cohort confirmed these findings. Conclusions: The i-BIO > 4 detected CA (GS > 0) with sensitivity of 87.9%, i-BIO ≥ 9 excluded patients without severe CA (GS < 35), specificity 79.8%. Validation of i-BIO confirmed the feasibility of i-BIO > 4 to separate patients with any CA with sensitivity 76.2%, and of i-BIO ≥ 9 to exclude atherosclerosis-free subjects with specificity of 84.0%. MDPI 2022-02-02 /pmc/articles/PMC8877383/ /pubmed/35207694 http://dx.doi.org/10.3390/jpm12020206 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Metelskaya, Victoria A. Gavrilova, Natalia E. Zhatkina, Maria V. Yarovaya, Elena B. Drapkina, Oxana M. A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation |
title | A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation |
title_full | A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation |
title_fullStr | A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation |
title_full_unstemmed | A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation |
title_short | A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation |
title_sort | novel integrated biomarker for evaluation of risk and severity of coronary atherosclerosis, and its validation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877383/ https://www.ncbi.nlm.nih.gov/pubmed/35207694 http://dx.doi.org/10.3390/jpm12020206 |
work_keys_str_mv | AT metelskayavictoriaa anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT gavrilovanataliae anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT zhatkinamariav anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT yarovayaelenab anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT drapkinaoxanam anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT metelskayavictoriaa novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT gavrilovanataliae novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT zhatkinamariav novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT yarovayaelenab novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation AT drapkinaoxanam novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation |